Clinical significance of FDG-PET/CT at the postoperative surveillance in the breast cancer patients

详细信息    查看全文

• 作者：Na Young Jung ; Ie Ryung Yoo ; Bong Joo Kang ; Sung Hun Kim ; Byung Joo Chae…
• 关键词：FDG ; PET/CT ; Breast cancer ; Recurrence ; Surveillance
• 刊名：Breast Cancer
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：23
• 期：1
• 页码：141-148
• 全文大小：2,710 KB
• 参考文献：1.Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med. 2005;35(2):84–99.PubMed CrossRef
  2.Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol. 2000;18(20):3495–502.PubMed
  3.Anderson SJ, Wapnir I, Dignam JJ, Fisher B, Mamounas EP, Jeong JH, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol. 2009;27(15):2466–73.PubMed PubMedCentral CrossRef
  4.Wapnir IL, Anderson SJ, Mamounas EP, Geyer CE Jr, Jeong JH, Tan-Chiu E, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol. 2006;24(13):2028–37.PubMed CrossRef
  5.Kim TS, Moon WK, Lee DS, Chung JK, Lee MC, Youn YK, et al. Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer. World J Surg. 2001;25(7):829–34.PubMed CrossRef
  6.Kostakoglu L, Agress H, Jr, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. Radiographics. 2003;23(2):315–40 quiz 533.PubMed CrossRef
  7.Bohuslavizki KH, Klutmann S, Kroger S, Sonnemann U, Buchert R, Werner JA, et al. FDG PET detection of unknown primary tumors. J Nucl Med. 2000;41(5):816–22.PubMed
  8.Bar-Shalom R, Valdivia AY, Blaufox MD. PET imaging in oncology. Semin Nucl Med. 2000;30(3):150–85.PubMed CrossRef
  9.Gallowitsch HJ, Kresnik E, Gasser J, Kumnig G, Igerc I, Mikosch P, et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol. 2003;38(5):250–6.PubMed
  10.Litmanovich D, Gourevich K, Israel O, Gallimidi Z. Unexpected foci of (18)F-FDG uptake in the breast detected by PET/CT: incidence and clinical significance. Eur J Nucl Med Mol Imaging. 2009.
  11.Vranjesevic D, Filmont JE, Meta J, Silverman DH, Phelps ME, Rao J, et al. Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. J Nucl Med. 2002;43(3):325–9.PubMed
  12.Veit-Haibach P, Antoch G, Beyer T, Stergar H, Schleucher R, Hauth EA, et al. FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy. Br J Radiol. 2007;80(955):508–15.PubMed CrossRef
  13.Uematsu T, Yuen S, Yukisawa S, Aramaki T, Morimoto N, Endo M, et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. AJR Am J Roentgenol. 2005;184(4):1266–73.PubMed CrossRef
  14.Ohta M, Tokuda Y, Suzuki Y, Kubota M, Makuuchi H, Tajima T, et al. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun. 2001;22(8):875–9.PubMed CrossRef
  15.Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike K, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging. 2005;32(11):1253–8.PubMed CrossRef
  16.Hyun J, Yoo IR, Kim SH, Sohn HS, Chung SK. Clinical significance of small pulmonary nodules with little or no 18F-FDG uptake on PET/CT images of patients with nonthoracic malignancies. J Nucl Med. 2007;48(1):15–21.
  17.Ishimori T, Patel PV, Wahl RL. Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med. 2005;46(5):752–7.PubMed
  18.Brennan ME, Houssami N. Evaluation of the evidence on staging imaging for detection of asymptomatic distant metastases in newly diagnosed breast cancer. Breast. 2012;21(2):112–23.PubMed CrossRef
  19.Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, et al. Invasive breast cancer. J Natl Compr Canc Netw. 2011;9(2):136–222.PubMed
  20.Garami Z, Hascsi Z, Varga J, Dinya T, Tanyi M, Garai I, et al. The value of 18-FDG PET/CT in early-stage breast cancer compared to traditional diagnostic modalities with an emphasis on changes in disease stage designation and treatment plan. Eur J Surg Oncol. 2012;38(1):31–7.PubMed CrossRef
  21.Lee JH, Rosen EL, Mankoff DA. The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: part 2–response to therapy, other indications, and future directions. J Nucl Med. 2009;50(5):738–48.PubMed CrossRef
  22.Peare R, Staff RT, Heys SD. The use of FDG-PET in assessing axillary lymph node status in breast cancer: a systematic review and meta-analysis of the literature. Breast Cancer Res Treat. 2010;123(1):281–90.PubMed CrossRef
  23.Mankoff DA, Specht JM, Eubank WB, Kessler L. [(1)(8)F]fluorodeoxyglucose positron emission tomography-computed tomography in breast cancer: when… and when not? J Clin Oncol. 2012;30(12):1252–4.PubMed CrossRef
  
• 作者单位：Na Young Jung (1)
  Ie Ryung Yoo (1)
  Bong Joo Kang (1)
  Sung Hun Kim (1)
  Byung Joo Chae (2)
  Ye Young Seo (1)
  
  1. Departments of Radiology, Seoul St. Mary’s Hospital College of Medicine, The Catholic University of Korea, 505 Banpo-Dong, Seocho-Ku, Seoul, 137-040, Korea
  2. Department of Surgery, The Catholic University of Korea, Seoul, Korea
  
• 刊物主题：Surgical Oncology; Oncology; Surgery; Cancer Research;
• 出版者：Springer Japan
• ISSN：1880-4233

文摘

Aim We evaluated the clinical role of [18F]-2-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (FDG-PET/CT) compared with conventional imaging (CI) to detect locoregional recurrence or distant metastasis during postoperative surveillance of patients with breast cancer.